Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends

Biotech Giants' SG&A Expenses: A Decade of Divergence

__timestampAgios Pharmaceuticals, Inc.Neurocrine Biosciences, Inc.
Wednesday, January 1, 20141912000017986000
Thursday, January 1, 20153599200032480000
Friday, January 1, 20165071400068081000
Sunday, January 1, 201771124000169906000
Monday, January 1, 2018114145000248932000
Tuesday, January 1, 2019132034000354100000
Wednesday, January 1, 2020149070000433300000
Friday, January 1, 2021121445000583300000
Saturday, January 1, 2022121673000752700000
Sunday, January 1, 2023119903000887600000
Monday, January 1, 20241567840001007200000
Loading chart...

Unleashing insights

SG&A Expense Trends: A Tale of Two Biotechs

In the competitive world of biotechnology, managing expenses is crucial for sustained growth. This analysis of SG&A (Selling, General, and Administrative) expenses from 2014 to 2023 reveals intriguing trends for Neurocrine Biosciences, Inc. and Agios Pharmaceuticals, Inc. Over this period, Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing nearly 50 times from 2014 to 2023. In contrast, Agios Pharmaceuticals experienced a more modest growth, with expenses increasing by approximately 6 times.

A Decade of Financial Strategy

Neurocrine's aggressive expansion strategy is evident, with its SG&A expenses peaking at nearly $888 million in 2023, reflecting its commitment to scaling operations and market presence. Meanwhile, Agios Pharmaceuticals maintained a steadier pace, with expenses reaching around $120 million in the same year. This divergence highlights differing strategic priorities, with Neurocrine focusing on rapid growth and Agios on sustainable development.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025